2013
DOI: 10.1159/000347232
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Objectives: To replace 5-fluorouracil with capecitabine within a trial of induction chemotherapy followed by cetuximab plus radiotherapy (RT) in patients with locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Also, to replace cisplatin with cetuximab after induction chemotherapy. Methods: Docetaxel and cisplatin were given at 75 mg/m2, while capecitabine was initially given at 500 mg/m2 twice a day and subsequently escalated. The maximum tolerated dose was used f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
7
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(7 citation statements)
references
References 25 publications
0
7
0
Order By: Relevance
“…8,10,33 As a safer and more tolerable induction regimen, some authors maintain that cisplatin and docetaxel, with a range of options for the third drug. The 5-fluorouracil (5-FU) has been replaced by capecitabine, 29 ifosfamide, 24,26 cetuximab, 23 and gemcitabine. 34 Other authors have replaced docetaxel with paclitaxel 24,25,27,28 or split the docetaxel dose (biweekly docetaxel) 35 to reduce hematological toxicity, whereas others omit the third agent.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…8,10,33 As a safer and more tolerable induction regimen, some authors maintain that cisplatin and docetaxel, with a range of options for the third drug. The 5-fluorouracil (5-FU) has been replaced by capecitabine, 29 ifosfamide, 24,26 cetuximab, 23 and gemcitabine. 34 Other authors have replaced docetaxel with paclitaxel 24,25,27,28 or split the docetaxel dose (biweekly docetaxel) 35 to reduce hematological toxicity, whereas others omit the third agent.…”
Section: Discussionmentioning
confidence: 99%
“…Consequently, extensive efforts are ongoing to identify alternative schemes that are less toxic than but as effective as the TPF regimen for locally advanced HNSCC and safely allow the use of definitive concurrent treatment based on cisplatin and radiotherapy …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Therefore, these results challenge the axiom that increased doses are associated with improved response. This axiom may be true in the absence of side effects; however, the development of severe side effects frequently prevents the benefits of increased dosing from every being realized (16). Therefore, an optimal balance between clinical response and the development of side effects should be reached in order to maximize the clinical outcome of a given patient.…”
Section: Discussionmentioning
confidence: 99%
“…The principle axiom of chemotherapy has been that the highest tolerated (acceptable percentage of grade 3 and 4 toxicities) is the preferred regimen to use (16,17). Therefore, the degree of grade 3 and 4 toxicity observed is frequently a limitation to the accepted chemotherapeutic regimen, particularly as this limits the number of cycles that may be administered.…”
Section: Introductionmentioning
confidence: 99%